Stonegate Capital Partners has updated its coverage on Burcon Nutrascience Corporation (TSX: BU), highlighting the company's transition from technology validation to commercial execution. Burcon's first-quarter fiscal 2027 results, reported in August 2026, reveal a 54% sequential increase and a 273% year-over-year surge in revenue to $1.28 million. Active buying customers grew to 40 from over 30 in the prior quarter, and repeat purchasing is on the rise, indicating improving demand visibility.
Despite the revenue growth, the quarter was impacted by a $1.76 million inventory write-down, which masked a much narrower underlying gross loss. The company's focus now is on whether this customer traction can support the substantial second-half revenue ramp required to achieve its prior CY26 sales objective. The company had previously targeted $10 million in sales for calendar year 2026, which implies roughly $7.9 million in second-half sales—a significant increase from current levels.
Key to this ramp are capacity expansion and funding. Burcon is planning an up-to-$8.1 million financing to bridge liquidity and support the expansion of its Galesburg production facility. This expansion is critical to meeting the anticipated demand from its growing customer base. The company also continues to work toward positive cash flow, an important milestone for long-term sustainability.
According to Stonegate, the second-half ramp remains substantial, and the company's ability to execute on its capacity and financing plans will be crucial. The update emphasizes that while commercialization is gaining momentum, the execution levers of capacity and funding are now the primary focus. Investors will be watching closely to see if Burcon can deliver on its sales target and move closer to profitability.
For more details, please refer to the full announcement from Stonegate Capital Partners.
